Publications in collaboration with researchers from Centro de Investigación Médica Aplicada (38)

2025

  1. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial

    Nature Medicine, Vol. 31, Núm. 3, pp. 861-868

2024

  1. Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry

    STAR Protocols, Vol. 5, Núm. 1

  2. The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles

    Molecular Therapy Oncology, Vol. 32, Núm. 2

2023

  1. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393

  2. Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson's disease

    GLIA, Vol. 71, Núm. 3, pp. 571-587

  3. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378

  4. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 169-188

  5. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

  6. Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology

    Neoplasia (United States), Vol. 42

2022

  1. Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 26, pp. 246-264

  2. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

2021

  1. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

    Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820

  2. Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 20, pp. 23-33

2020

  1. RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases

    Neuro-Oncology Advances, Vol. 2, Núm. 1

  2. Sarcoma treatment in the era of molecular medicine

    EMBO Molecular Medicine, Vol. 12, Núm. 11

  3. Somatic and germline analysis of a familial Rothmund–Thomson syndrome in two siblings with osteosarcoma

    npj Genomic Medicine, Vol. 5, Núm. 1

2019

  1. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models

    Acta neuropathologica communications, Vol. 7, Núm. 1, pp. 64

  2. Destress and do not suppress: Targeting adrenergic signaling in tumor immunosuppression

    Journal of Clinical Investigation, Vol. 129, Núm. 12, pp. 5086-5088

  3. GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory

    Neuro-Oncology Advances, Vol. 1, Núm. 1

  4. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1